June 29, 2021 -- Charles River Laboratories has completed its acquisition of Vigene for $292.5 million in cash. In addition to the initial purchase price, the transaction includes payments of up to $57.5 million, contingent on future performance.
The acquisition will enhance Charles River's gene therapy capabilities within the cell and gene therapy contract development and manufacturing organization (CDMO) sector. Adding Vigene to the business will also enable Charles River clients to conduct analytical testing, process development, and manufacturing for advanced modalities with a single partner.
Vigene has become part of Charles River's Manufacturing Solutions segment, which was renamed from Manufacturing Support to reflect the segment's broader capabilities with the addition of the cell and gene therapy CDMO business.